As previously discussed, the constitutive activation of signaling pathways like JAK-STAT and SRC/TNK2 in CSF3R-altered neoplasms presents opportunities for targeted interventions with documented efficacy using JAK inhibitors such as ruxolitinib in these neoplasms [11,29]. This evidence concerns the gene TNK2 and neoplasm.